Jiangsu Hengrui Pharmaceuticals , China’s biggest drugmaker by market value, reported fourth-quarter profit below market expectations on Wednesday, as income from business development deals has failed to appear.
The specialist in oncology, neurology, immunology, respiratory, metabolic and cardiovascular drugs has expanded licensing deals and developed more innovative drugs amid Beijing’s centralised bulk buying programmes, which have squeezed generic drug… [559 chars]
Source: Reuters | Published: 2026-03-25T13:33:23Z
Credit: Reuters
